The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Moderna Stock Forecast

Recent Moderna Stock Price   Moderna Stock Forecast Price
$193.24 Moderna stock forecast: higher
+17.61%
$227.27
 As of 2023-01-27
Recent Moderna Analyst Ratings Breakdown
  Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong buy ratings: 6 6 6 5
Buy ratings: 0 0 0 0
Hold ratings: 7 8 8 8
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 2.08 2.14 2.14 2.23
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.

The presented Moderna stock forecast (traded under symbol MRNA), for forward-twelve-months price target as shown at the top of this page, gives you the average Moderna stock forecast for forward target price for symbol MRNA, across the 11 analysts covering Moderna (MRNA), as reported in data provided by Zacks Investment Research via Quandl.com.

Investors should also take note that the median Moderna stock forecast price target (i.e. representing the middle ground number where half of analysts had a higher Moderna stock forecast and half had a lower Moderna stock forecast) was $208.0 as of 2023-01-27 (which is a different mathematical metric versus taking the average or mean), while the highest Moderna stock forecast in the analyst group was $506.0, and the lowest Moderna stock forecast in the analyst group was $111.0, with a standard deviation of $108.98. Get the latest Zacks research report on MRNA — FREE

Slideshow Top Analyst Picks of the Dow
Slideshow The Top 20 Largest U.S. Stocks By Market Cap

Company Name:  Moderna Inc
Website:  www.modernatx.com
Sector:  Biotechnology
Number of ETFs Holding MRNA:  110
Total Market Value Held by ETFs:  $8.49B
Total Market Capitalization:  $74.17B
% of Market Cap. Held by ETFs:  11.44%
January 29, 2023    5:15 PM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree MRNA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.92 out of 4)
20th percentile
(ranked lower than approx. 80% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Moderna Stock Forecast (MRNA) | www.TheOnlineInvestor.com | Copyright © 1998 - 2023, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.